AFM
HZNP

Anson Funds Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Anson Funds Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-20,000
Closed -$2.31M – 217
2023
Q3 		$2.31M Buy
+20,000
New +$2.15M 0.47% 50
2023
Q2 		– Sell
-60,000
Closed -$6.55M – 224
2023
Q1 		$6.55M Buy
60,000
+35,000
+140% +$3.87M 1.07% 24
2022
Q4 		$2.85M Buy
+25,000
New +$2.08M 0.47% 45

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Anson Funds Management's HZNP Position: Q4 2023 in Review

Anson Funds Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 20,000 shares — an estimated $2.31M sold.

Anson Funds Management first reported a position in HZNP in Q4 2022 and held it in 3 quarters. The position peaked at $6.55M in Q1 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Anson Funds Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Anson Funds Management sold 20,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $2.31M.
  • Anson Funds Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 3 quarters.
  • Anson Funds Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $6.55M in Q1 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Anson Funds Management's 13F filing for Q4 2023, filed 14 Feb 2024.